1. Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety
- Author
-
Johannes Werzowa, Manfred Hecking, Elisabeth Schwaiger, Sabine Schmaldienst, Andrea Tura, Giovanni Pacini, Marlies Antlanger, Lukas Burghart, Thomas Wrba, Chantal Kopecky, Lorenzo Signorini, Marcus D. Säemann, and Robin Ristl
- Subjects
Blood Glucose ,Graft Rejection ,Male ,medicine.medical_treatment ,Islets of Langerhans Transplantation ,kidney transplantation/nephrology ,Pilot Projects ,030230 surgery ,Postoperative Complications ,0302 clinical medicine ,Glucosides ,Risk Factors ,Clinical endpoint ,Insulin ,Immunology and Allergy ,Pharmacology (medical) ,Prospective Studies ,Graft Survival ,Middle Aged ,Prognosis ,Body Fluids ,Body Composition ,Female ,endocrinology/diabetology ,Patient Safety ,Brief Communications ,medicine.medical_specialty ,metabolism/metabolite ,Urinary system ,Urology ,Renal function ,kidney (allograft) function/dysfunction ,Carbohydrate metabolism ,Brief Communication ,clinical research/practice ,diabetes: new onset/posttransplant ,03 medical and health sciences ,Early Medical Intervention ,Diabetes mellitus ,Empagliflozin ,medicine ,Humans ,Benzhydryl Compounds ,Sodium-Glucose Transporter 2 Inhibitors ,Retrospective Studies ,Transplantation ,business.industry ,medicine.disease ,Ketoacidosis ,Diabetes Mellitus, Type 2 ,business ,Follow-Up Studies - Abstract
The safety and efficacy of sodium‐glucose cotransporter 2 inhibitors in posttransplantation diabetes mellitus is unknown. We converted stable kidney transplant patients to 10 mg empagliflozin, aiming at replacing their insulin therapy (, Empagliflozin appears safe, but exerts a weak antihyperglycemic effect, suggesting that the drug should be used as add‐on therapy under close medical supervision in patients with stable post–kidney transplantation diabetes mellitus.
- Published
- 2019